Trader Savara - SVRA CFD
Ajouter aux favoris- Résumé
- Données historiques
- Événements
- Compte de résultat
- Bilan
- Flux de trésorerie
- Capital
Conditions de trading
| Écart | 0.06 | ||||||||
|
Frais de position longue en overnight
Long position overnight fee
Aller vers la plateforme | -0.024068% | ||||||||
|
Frais de position courte en overnight
Short position overnight fee
Aller vers la plateforme | 0.001846% | ||||||||
| Durée des frais en overnight | 21:00 (UTC) | ||||||||
| Quantité minimale négociée | 1 | ||||||||
| Devise | USD | ||||||||
| Marge | 20% | ||||||||
| Bourse | United States of America | ||||||||
| Commission sur la négociation | 0% |
*Information provided by Capital.com
Chiffres clés
| Fermeture précédente* | 1.95 |
| Ouvert* | 1.93 |
| Variation sur 1 an* | 56.91% |
| Fourchette du jour* | 1.81 - 1.94 |
| Fourchette sur 52 semaines | 1.06-2.85 |
| Volume moyen (10 jours) | 232.57K |
| Volume moyen (3 mois) | 5.08M |
| Capitalisation boursière | 234.93M |
| Ratio C/B | -100.00K |
| Actions en circulation | 114.04M |
| Revenu | N/A |
| EPS | -0.27 |
| Dividende (rendement en %) | N/A |
| Bêta | 0.92 |
| Prochaine date de publication des résultats | Mar 28, 2023 |
Toutes les données sont fournies par Refinitiv, à l'exception des données marquées d'un astérisque, qui sont des *données fournies par Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Clôture | Change | Change (%) | Ouverture | High | Low |
|---|---|---|---|---|---|---|
| Mar 22, 2023 | 1.88 | -0.02 | -1.05% | 1.90 | 1.94 | 1.80 |
| Mar 21, 2023 | 1.95 | -0.12 | -5.80% | 2.07 | 2.08 | 1.91 |
| Mar 20, 2023 | 2.03 | 0.04 | 2.01% | 1.99 | 2.08 | 1.98 |
| Mar 17, 2023 | 2.00 | -0.01 | -0.50% | 2.01 | 2.11 | 1.96 |
| Mar 16, 2023 | 2.14 | 0.13 | 6.47% | 2.01 | 2.22 | 2.01 |
| Mar 15, 2023 | 2.17 | 0.03 | 1.40% | 2.14 | 2.23 | 2.11 |
| Mar 14, 2023 | 2.17 | 0.13 | 6.37% | 2.04 | 2.28 | 2.04 |
| Mar 13, 2023 | 2.08 | 0.10 | 5.05% | 1.98 | 2.21 | 1.95 |
| Mar 10, 2023 | 2.08 | -0.31 | -12.97% | 2.39 | 2.41 | 1.96 |
| Mar 9, 2023 | 2.46 | 0.04 | 1.65% | 2.42 | 2.48 | 2.41 |
| Mar 8, 2023 | 2.48 | 0.13 | 5.53% | 2.35 | 2.48 | 2.33 |
| Mar 7, 2023 | 2.43 | 0.01 | 0.41% | 2.42 | 2.48 | 2.41 |
| Mar 6, 2023 | 2.41 | 0.12 | 5.24% | 2.29 | 2.44 | 2.29 |
| Mar 3, 2023 | 2.33 | -0.18 | -7.17% | 2.51 | 2.51 | 2.28 |
| Mar 2, 2023 | 2.52 | 0.12 | 5.00% | 2.40 | 2.55 | 2.40 |
| Mar 1, 2023 | 2.46 | -0.02 | -0.81% | 2.48 | 2.51 | 2.42 |
| Feb 28, 2023 | 2.46 | 0.06 | 2.50% | 2.40 | 2.49 | 2.40 |
| Feb 27, 2023 | 2.44 | 0.04 | 1.67% | 2.40 | 2.49 | 2.40 |
| Feb 24, 2023 | 2.50 | -0.03 | -1.19% | 2.53 | 2.61 | 2.50 |
| Feb 23, 2023 | 2.60 | -0.04 | -1.52% | 2.64 | 2.73 | 2.56 |
Savara Events
| Heure (UTC) (UTC) | Pays | Événement |
|---|---|---|
| No events scheduled | ||
- Annuel
- Trimestriel
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Revenu total | 0 | 0.257 | 0 | 0 | 0 |
| Revenu | 0 | 0.257 | 0 | ||
| Total des frais d'exploitation | 41.477 | 49.557 | 79.025 | 70.045 | 31.772 |
| Total des frais de vente/Généraux/Admin | 12.35 | 14.264 | 13.081 | 10.654 | 8.881 |
| Recherche et développement | 28.991 | 35.038 | 38.781 | 37.173 | 18.512 |
| Depreciation / Amortization | 0.136 | 0.255 | 0.311 | 0.526 | 0.363 |
| Charges (revenus) inhabituelles | 0 | 26.852 | 21.692 | 4.016 | |
| Produits d'exploitation | -41.477 | -49.3 | -79.025 | -70.045 | -31.772 |
| Produits (charges) d'intérêts, nets Hors exploitation | -2.381 | -1.208 | -0.361 | 0.018 | -1.659 |
| Autres, nets | 0.844 | 0.893 | 1.213 | 1.454 | |
| Résultat net avant impôts | -43.014 | -49.615 | -78.173 | -68.573 | -33.431 |
| Résultat net après impôts | -43.014 | -49.615 | -78.173 | -61.516 | -32.597 |
| Résultat net avant éléments extra | -43.014 | -49.615 | -78.173 | -61.516 | -32.597 |
| Résultat net | -43.014 | -49.615 | -78.173 | -61.516 | -29.797 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -43.014 | -49.615 | -78.173 | -61.516 | -33.579 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -43.014 | -49.615 | -78.173 | -61.516 | -30.779 |
| Résultat net dilué | -43.014 | -49.615 | -78.173 | -61.516 | -30.779 |
| Moyenne pondérée des actions diluées | 133.919 | 59.3091 | 40.0278 | 33.3007 | 17.5211 |
| BPA dilué hors éléments extraordinaires | -0.32119 | -0.83655 | -1.95297 | -1.84729 | -1.91649 |
| BPA dilué normalisé | -0.17185 | -0.83655 | -1.28214 | -1.19589 | -1.7675 |
| Total des éléments extraordinaires | 2.8 | ||||
| Total Adjustments to Net Income | -0.982 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Revenu total | 0 | 0 | 0 | 0 | 0 |
| Total des frais d'exploitation | 8.046 | 10.639 | 9.972 | 10.452 | 10.414 |
| Total des frais de vente/Généraux/Admin | 2.354 | 3.019 | 3.4 | 3.153 | 2.778 |
| Recherche et développement | 5.684 | 7.618 | 6.532 | 7.252 | 7.589 |
| Depreciation / Amortization | 0.008 | 0.002 | 0.04 | 0.047 | 0.047 |
| Produits d'exploitation | -8.046 | -10.639 | -9.972 | -10.452 | -10.414 |
| Produits (charges) d'intérêts, nets Hors exploitation | -0.583 | -0.642 | -0.574 | -0.515 | -0.65 |
| Autres, nets | 0.329 | -0.029 | 0 | 0.026 | 0.847 |
| Résultat net avant impôts | -8.3 | -11.31 | -10.546 | -10.941 | -10.217 |
| Résultat net après impôts | -8.3 | -11.31 | -10.546 | -10.941 | -10.217 |
| Résultat net avant éléments extra | -8.3 | -11.31 | -10.546 | -10.941 | -10.217 |
| Résultat net | -8.3 | -11.31 | -10.546 | -10.941 | -10.217 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -8.3 | -11.31 | -10.546 | -10.941 | -10.217 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -8.3 | -11.31 | -10.546 | -10.941 | -10.217 |
| Résultat net dilué | -8.3 | -11.31 | -10.546 | -10.941 | -10.217 |
| Moyenne pondérée des actions diluées | 152.769 | 133.919 | 152.588 | 152.461 | 76.9924 |
| BPA dilué hors éléments extraordinaires | -0.05433 | -0.08445 | -0.06911 | -0.07176 | -0.1327 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA dilué normalisé | -0.05433 | 0.06489 | -0.06911 | -0.07176 | -0.1327 |
| Revenu | 0 | 0 |
- Annuel
- Trimestriel
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 165 | 85.121 | 124.067 | 113.344 | 97.864 |
| Espèces et placements à court terme | 161.171 | 82.188 | 121.761 | 110.83 | 94.313 |
| Trésorerie et équivalents | 34.012 | 22.88 | 49.804 | 24.301 | 22.121 |
| Total des créances, nettes | 1.144 | 1.695 | 1.617 | 1.684 | 1.03 |
| Prepaid Expenses | 2.329 | 1.044 | 0.431 | 0.723 | 2.287 |
| Other Current Assets, Total | 0.356 | 0.194 | 0.258 | 0.107 | 0.234 |
| Total Assets | 176.598 | 97.745 | 136.203 | 152.287 | 159.628 |
| Property/Plant/Equipment, Total - Net | 0.373 | 0.356 | 1.025 | 0.522 | 0.925 |
| Goodwill, Net | 26.918 | 27.082 | |||
| Intangibles, Net | 11.274 | 12.218 | 11.111 | 11.372 | 33.626 |
| Other Long Term Assets, Total | -0.049 | 0.05 | 0.131 | 0.131 | |
| Total Current Liabilities | 14.66 | 8.174 | 10.88 | 7.254 | 6.015 |
| Accounts Payable | 1.443 | 2.595 | 3.409 | 3.879 | 2.784 |
| Accrued Expenses | 4.884 | 5.579 | 5.471 | 3.058 | 2.966 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 8.333 | 2 | 0.041 | 0.265 | |
| Total Liabilities | 32.1 | 33.362 | 34.505 | 44.068 | 40.319 |
| Total Long Term Debt | 17.323 | 25.104 | 23.112 | 24.53 | 15.072 |
| Long Term Debt | 17.323 | 25.104 | 23.112 | 24.53 | 14.775 |
| Capital Lease Obligations | 0 | 0.297 | |||
| Deferred Income Tax | 0 | 7.181 | |||
| Other Liabilities, Total | 0.117 | 0.084 | 0.513 | 12.284 | 12.051 |
| Total Equity | 144.498 | 64.383 | 101.698 | 108.219 | 119.309 |
| Preferred Stock - Non Redeemable, Net | 0 | ||||
| Common Stock | 0.116 | 0.055 | 0.052 | 0.036 | 0.032 |
| Additional Paid-In Capital | 444.898 | 320.893 | 309.555 | 237.702 | 186.522 |
| Retained Earnings (Accumulated Deficit) | -300.521 | -257.507 | -207.892 | -129.719 | -68.203 |
| Other Equity, Total | 0.054 | 0.942 | -0.017 | 0.2 | 0.958 |
| Total Liabilities & Shareholders’ Equity | 176.598 | 97.745 | 136.203 | 152.287 | 159.628 |
| Total Common Shares Outstanding | 114.037 | 54.153 | 50.7904 | 35.1461 | 30.5095 |
| Total Preferred Shares Outstanding | 0 | ||||
| Investissements à court terme | 127.159 | 59.308 | 71.957 | 86.529 | 72.192 |
| Property/Plant/Equipment, Total - Gross | 2.452 | 2.329 | 2.699 | 1.89 | 1.776 |
| Accumulated Depreciation, Total | -2.079 | -1.973 | -1.674 | -1.368 | -0.851 |
| Other Current Liabilities, Total | 0 | 0.276 | |||
| Unrealized Gain (Loss) | -0.049 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 154.537 | 165 | 174.584 | 183.488 | 194.802 |
| Espèces et placements à court terme | 151.797 | 161.171 | 170.806 | 180.671 | 192.713 |
| Trésorerie et équivalents | 79.227 | 34.012 | 44.699 | 40.653 | 55.982 |
| Investissements à court terme | 72.57 | 127.159 | 126.107 | 140.018 | 136.731 |
| Total des créances, nettes | 1.149 | 1.144 | 1.207 | 1.462 | 1.423 |
| Prepaid Expenses | 1.285 | 2.329 | 2.439 | 1.167 | 0.445 |
| Other Current Assets, Total | 0.306 | 0.356 | 0.132 | 0.188 | 0.221 |
| Total Assets | 166.209 | 176.598 | 187.274 | 196.433 | 207.63 |
| Property/Plant/Equipment, Total - Net | 0.064 | 0.073 | 0.091 | 0.102 | 0.124 |
| Intangibles, Net | 11.06 | 11.274 | 11.547 | 11.834 | 11.676 |
| Other Long Term Assets, Total | 0.548 | 0.251 | 1.052 | 1.009 | 1.028 |
| Total Current Liabilities | 16.323 | 14.66 | 10.661 | 5.635 | 7.207 |
| Accounts Payable | 1.296 | 1.443 | 1.279 | 2.144 | 2.723 |
| Accrued Expenses | 2.527 | 4.884 | 5.215 | 3.491 | 4.484 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 29.734 | 32.1 | 32.045 | 31.051 | 32.509 |
| Total Long Term Debt | 13.309 | 17.323 | 21.35 | 25.381 | 25.244 |
| Long Term Debt | 13.309 | 17.323 | 21.35 | 25.381 | 25.244 |
| Other Liabilities, Total | 0.102 | 0.117 | 0.034 | 0.035 | 0.058 |
| Total Equity | 136.475 | 144.498 | 155.229 | 165.382 | 175.121 |
| Common Stock | 0.116 | 0.116 | 0.115 | 0.114 | 0.114 |
| Additional Paid-In Capital | 445.471 | 444.898 | 444.04 | 443.341 | 442.246 |
| Retained Earnings (Accumulated Deficit) | -308.821 | -300.521 | -289.211 | -278.665 | -267.724 |
| Unrealized Gain (Loss) | -0.137 | -0.049 | -0.011 | -0.001 | -0.025 |
| Other Equity, Total | -0.154 | 0.054 | 0.296 | 0.593 | 0.51 |
| Total Liabilities & Shareholders’ Equity | 166.209 | 176.598 | 187.274 | 196.433 | 207.63 |
| Total Common Shares Outstanding | 114.041 | 114.037 | 113.867 | 113.848 | 113.579 |
| Current Port. of LT Debt/Capital Leases | 12.5 | 8.333 | 4.167 |
- Annuel
- Trimestriel
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Revenu net/Ligne de départ | -43.014 | -49.615 | -78.173 | -61.516 | -29.797 |
| Liquidités provenant des activités d'exploitation | -40.081 | -39.836 | -45.123 | -39.275 | -28.234 |
| Liquidités provenant des activités d'exploitation | 0.136 | 0.255 | 1.01 | 0.526 | 0.363 |
| Deferred Taxes | -7.057 | -2.82 | |||
| Éléments non monétaires | 5.643 | 11.229 | 31.193 | 26.326 | 6.051 |
| Intérêts payés en espèces | 1.969 | 2.47 | 2.099 | 1.406 | |
| Variation du fonds de roulement | -2.846 | -1.705 | 0.847 | 2.446 | -2.031 |
| Flux de trésorerie liés aux activités d'investissement | -69.456 | 9.053 | 15.74 | -13.619 | -69.115 |
| Dépenses d'investissement | -0.057 | -3.294 | -0.148 | -0.141 | -0.495 |
| Autres éléments de flux de trésorerie d'investissement, total | -69.399 | 12.347 | 15.888 | -13.478 | -68.62 |
| Flux de trésorerie provenant des activités de financement | 120.806 | 3.689 | 54.908 | 55.193 | 106.089 |
| Éléments de flux de trésorerie de financement | -0.078 | ||||
| Émission (remboursement) d'actions, nette | 120.884 | 4.203 | 54.949 | 46.374 | 91.653 |
| Émission (remboursement) de la dette, nette | 0 | -0.514 | -0.041 | 8.819 | 14.436 |
| Variation nette de la trésorerie | 11.132 | -26.924 | 25.503 | 2.18 | 8.748 |
| Effets de change | -0.137 | 0.17 | -0.022 | -0.119 | 0.008 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -8.3 | -43.014 | -31.704 | -21.158 | -10.217 |
| Cash From Operating Activities | -8.425 | -40.081 | -30.718 | -21.791 | -9.597 |
| Cash From Operating Activities | 0.008 | 0.136 | 0.134 | 0.094 | 0.047 |
| Non-Cash Items | 1.04 | 5.643 | 4.107 | 2.793 | 1.361 |
| Cash Interest Paid | 0.484 | 1.969 | 1.469 | 0.974 | 0.484 |
| Changes in Working Capital | -1.173 | -2.846 | -3.255 | -3.52 | -0.788 |
| Cash From Investing Activities | 53.665 | -69.456 | -68.188 | -81.171 | -77.739 |
| Capital Expenditures | -0.057 | -0.017 | -0.006 | 0 | |
| Other Investing Cash Flow Items, Total | 53.665 | -69.399 | -68.171 | -81.165 | -77.739 |
| Cash From Financing Activities | -0.001 | 120.806 | 120.8 | 120.79 | 120.466 |
| Issuance (Retirement) of Stock, Net | 0 | 120.884 | 120.8 | 120.79 | 120.466 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | |
| Foreign Exchange Effects | -0.024 | -0.137 | -0.075 | -0.055 | -0.028 |
| Net Change in Cash | 45.215 | 11.132 | 21.819 | 17.773 | 33.102 |
| Financing Cash Flow Items | -0.001 | -0.078 |
| Nom de l'investisseur | Catégorie de l'investisseur | Pourcentage de l'encours | Actions détenues | Changement d'actions | Date d'avoirs | Taux du chiffre d'affaires |
|---|---|---|---|---|---|---|
| New Enterprise Associates (NEA) | Venture Capital | 21.1655 | 24137931 | 0 | 2022-12-31 | LOW |
| Bain Capital Life Sciences Investors, LLC | Investment Advisor | 10.1913 | 11622598 | 0 | 2022-12-31 | LOW |
| Farallon Capital Management, L.L.C. | Hedge Fund | 8.8869 | 10134961 | 226875 | 2022-12-31 | MED |
| Caxton Associates LP | Hedge Fund | 6.0473 | 6896551 | 0 | 2022-12-31 | HIGH |
| Adage Capital Management, L.P. | Hedge Fund | 6.0192 | 6864551 | 0 | 2022-12-31 | LOW |
| VR Adviser, LLC | Venture Capital | 5.5694 | 6351531 | 164249 | 2022-12-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.2147 | 4806573 | 1527 | 2022-12-31 | LOW |
| AXA Investment Managers UK Ltd. | Investment Advisor/Hedge Fund | 2.9882 | 3407887 | -18328 | 2022-12-31 | MED |
| Ramsay (David A) | Individual Investor | 1.8424 | 2101142 | 154890 | 2022-12-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.8985 | 1024702 | 5639 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8902 | 1015212 | 3993 | 2022-12-31 | LOW |
| Sio Capital Management, LLC | Hedge Fund | 0.7597 | 866448 | 10020 | 2022-12-31 | HIGH |
| Pauls Matthew | Individual Investor | 0.5668 | 646354 | 325000 | 2022-12-13 | MED |
| UBS O'Connor LLC | Hedge Fund | 0.3958 | 451441 | 70611 | 2022-12-31 | HIGH |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.3392 | 386793 | 0 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.235 | 268011 | -3600 | 2022-12-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 0.2308 | 263187 | -19124 | 2022-12-31 | HIGH |
| QS Investors, LLC | Investment Advisor/Hedge Fund | 0.2135 | 243500 | 239500 | 2021-06-30 | LOW |
| Susquehanna International Group, LLP | Investment Advisor | 0.1721 | 196242 | 128898 | 2022-12-31 | MED |
| Franklin Advisers, Inc. | Investment Advisor/Hedge Fund | 0.1612 | 183880 | 0 | 2022-12-31 | LOW |
Pourquoi choisir capital.com? Nos chiffres parlent d'eux-mêmes.
Capital.com Group500K+
Tradeurs
92K+
Clients actifs par mois
$53M+
Volume d'investissement par mois
$30M+
Retrait par mois
Trading calculator
Calculez votre P&L hypothétique si vous aviez ouvert une transaction CFD à une certaine date (sélectionnez une date) et l'aviez fermée à une autre date (sélectionnez une date).
Trade commission
0
- 1:1
Effet de levier
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Ouverture
Clôture
Short Long
Savara Company profile
À propos de Savara
Savara Inc. est une société en phase clinique. La société se concentre sur les maladies respiratoires rares. Le programme principal de la société, la solution pour nébuliseur molgramostim (molgramostim), est un facteur de stimulation des colonies de granulocytes-macrophages inhalé en phase III de développement pour la protéinose alvéolaire pulmonaire auto-immune (aPAP). Le Molgramostim, une formulation inhalée de GM-CSF humain recombinant, est en cours de développement pour le traitement de la PPAA. La protéinose alvéolaire pulmonaire (PAP) est une maladie pulmonaire rare caractérisée par l'accumulation de surfactant dans les alvéoles ou sacs d'air des poumons.
| Industry: | Bio Therapeutic Drugs |
6836 Bee Cave Road
Building 3, Suite 201
AUSTIN
TEXAS 78746
US
Compte de résultat
- Annual
- Quarterly
Les gens regardent aussi
Êtes-vous toujours à la recherche d'un broker de confiance?
Rejoignez les plus de 500 000 traders du monde entier qui ont choisi de trader avec Capital.com